News | March 14, 2022
Applications for PLI in bulk drugs extended till March 31st 2022
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers releases guidelines for the scheme
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The money will be donated to the United Nations Children’s Fund (UNICEF)
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Subscribe To Our Newsletter & Stay Updated
